Skip to main content
Equibles
ACRV logo

ACRV · Acrivon Therapeutics, Inc.

Track ACRV — free

Use ACRV with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ACRV

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.06 -0.09 (-4.19%) At close · Aug 28
Rebalance outlook locked
Market Cap
$88.28M
Shares
42.85M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.06 Open$2.16 Day$2.05–2.19 52W close$1.29–3.01 Avg vol 30d351K Short int1.2M · 2.9% float · 4.1d Short vol34% Last earningsMay 26, 2026 DataNov 2022–Aug 2026 Filing10-Q · Aug 12

Up next

Next earnings call
Nov 23, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 12, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.39
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +11%
above
Price vs 50-day avg +14%
above
RSI (14) 56
neutral
MACD trend Positive
52-week position 45%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +37%
trailing
6-month return +29%
trailing
YTD return −15%
this year
Relative strength +15%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+5% holders QoQ · +6 funds added
Insider flow Distributing
Net -$39.8K over 90 days · 100% sells
Short interest Falling
2.88% of float · ▼ -8.8% MoM · 4.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
46 holders — mid 3-yr range
Squeeze score 62
elevated · 0–100
Fundamentals
Fair
EPS growth +15%
Y/Y
Free cash flow $-65.3M
Quant / Vol
risk profile
Very High
Volatility 95%
annualized · 1-yr
Max drawdown −57%
past year
ATR 6.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+11% Bullish
Price vs 50-day avg
+14% Bullish
RSI (14)
56 Neutral
MACD trend
Positive Bullish
52-week position
45% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+5% holders QoQ · +6 funds added
Insider flow Distributing
Net -$39.8K over 90 days · 100% sells
Short interest Falling
2.88% of float · ▼ -8.8% MoM · 4.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
46 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 45% Range high $3
vs 200-day avg +11% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Approximate Cash and Investments $118.6M 31-Dec-2025 —
Approximate Fully Diluted Shares Outstanding 45.1M 31-Dec-2025 —
cORR 52% serous EC —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ACRV
Acrivon Therapeutics, Inc.
this stock
$88.28M -14.5% — — 2.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +2.9% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $65.12B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
46
% held
49.9%
Net QoQ
+5.2M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
15
View
Short & Settlement
Short Interest Falling
Shares short
1.2M
Days to cover
4.1d
Change
-119.1K sh
View
Short Volume
Short vol %
34%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
3.9K
Value
$6.2K
As of
Jul 27, 2026
View
Off-Exchange
Off-exchange %
48.6%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$39.8K
Buyers / Sellers
0 / 6
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-77.9M
EPS diluted
$-2.02
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
12
View
Proposed Sales
Value
$30.6K
Shares
14.0K
Filed
Aug 25, 2026
View
Exempt Offerings
Offering
$100.0M
Filed
Nov 23, 2021
View
Earnings & Events
Earnings Calls
Last call
May 26, 2026
View
Investor Relations
Latest news
Acrivon Reports Second Quarter 20…
Published
Aug 12, 2026
View

Performance

5D 20D 120D MTD YTD
ACRV -6.8% +37.3% +28.8% +37.3% -14.5%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -7.3% +34.3% +15.3% +34.3% -27.3%
Key facts CIK 1781174 CUSIP 004890109 13F (30d) 44 filings 44 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)